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The role of receptor tyrosine kinases (RTKs) in transmembrane signaling is well established. 
Recently, ligand-dependent translocation of RTKs to the nucleus has been reported, but 
the functional importance of this process remains unclear. In this issue, Sardi et al. (2006) 
provide evidence for direct signaling in the nucleus by an intracellular ErbB4 receptor frag-
ment that is released upon receptor activation by ligand. The fragment forms a complex 
with the adaptor TAB2 and the corepressor N-CoR and transits to the nucleus, where it 
represses transcription of genes that promote the formation of astrocytes.Cell 127, October 6, 2006 ©2006 Elsevier Inc. 45Following discovery of the first growth factors, nerve 
growth factor (NGF) and epidermal growth factor (EGF), it 
became clear that NGF, EGF, and hormones such as insulin 
mediate their distinct pleiotropic responses by binding to 
and activating cell-surface receptors endowed with intrin-
sic tyrosine kinase activity, designated receptor tyrosine 
kinases (RTKs) (reviewed in Schlessinger, 2000; Blume-
Jensen and Hunter, 2001). RTKs transmit the activation 
signal across the plasma membrane, and many studies 
have demonstrated that the receptors, and not the growth 
factors, mediate the pleiotropic cellular responses. Growth 
factors recognize and activate their cognate receptors and 
stimulate receptor dimerization, tyrosine kinase activation, 
and autophosphorylation (reviewed in Schlessinger, 2000). 
The autophosphorylated RTKs recruit and activate a recep-
tor-specific complement of intracellular signaling pathways 
that relay information to the nucleus and other intracellular 
compartments (Figure 1) (reviewed in Schlessinger, 2000; 
Blume-Jensen and Hunter, 2001; Pawson et al., 2001; Levy 
and Darnell, 2002).
Beyond this well-established mechanism of RTK sig-
naling, direct communication between the membrane 
and nucleus by ligand-dependent nuclear localization 
of RTKs has also been reported. In a few cases, such 
as the EGF receptor, nuclear translocation of the intact 
receptor has been proposed, although the mechanistic 
basis for this, and its functional relevance, is extremely 
unclear (reviewed in Carpenter, 2003a; Krolewski, 2005; 
Massie and Mills, 2006). By contrast, Carpenter’s group 
has shown that ErbB4, an RTK that binds to neuregulin 1, 
is cleaved by a dual-protease system following the bind-
ing of ligand. Ligand binding promotes an initial cleavage 
event in the ErbB4 extracellular juxtamembrane domain 
(mediated by tumor necrosis factor α-converting enzyme, 
or TACE), followed by a second cleavage event within 
the transmembrane domain that is mediated by prese-
nilin/γ-secretase (Figure 1). An active soluble form of the ErbB4 cytoplasmic region is thus liberated (Carpenter, 
2003a, 2003b) and is translocated into the nucleus with 
potential functional consequences (Ni et al., 2001). A 
similar mechanism involving sequential cleavages in the 
juxtamembrane and transmembrane domains was pre-
viously established for the membrane-bound proteins 
Notch, amyloid precursor protein (APP), and sterol regu-
latory element-binding protein 2 (SREBP2). SREBP2 is a 
membrane-bound cholesterol sensor that acts as a tran-
scription factor in the nucleus (Goldstein et al., 2006). In 
dual-protease processing of SREBP2, the first cleavage 
is performed by a serine protease belonging to the sub-
tilisin family, and the second is mediated by a Zn2+ metal-
loproteinase. It was shown that the liberated soluble form 
of SREBP2 contains a nuclear localization signal (NLS), 
a DNA binding domain, and a transcriptional activation 
domain that activates genes required for cholesterol pro-
duction (Goldstein et al., 2006).
In this issue of Cell, Sardi et al. (2006) describe a mech-
anism initiated by dual-protease signaling for the regu-
lation of gene transcription and cell fate through direct 
nuclear signaling by an ErbB4 fragment. Transcriptional 
repression by a complex involving this ErbB4 fragment 
controls the timing of astrogenesis in the developing 
cerebral cortex of mice.
Canonical ErbB4 Signaling at the Plasma Membrane
ErbB4 is a member of the EGF receptor (EGFR) family of 
RTKs (Plowman et al., 1993), which are activated at the 
cell membrane by neuregulins and other growth factors 
such as betacellulin (BTC) and heparin-binding EGF-like 
growth factor (reviewed in Carpenter, 2003b). Like other 
RTKs, ErbB4 is composed of an extracellular ligand-bind-
ing region that is connected to a cytoplasmic portion via a 
single transmembrane (TM) domain (reviewed in Schless-
inger, 2000; Carpenter, 2003b). The cytoplasmic portion 
of ErbB4 contains a conserved tyrosine kinase domain 
Figure 1. Canonical and Nuclear ErbB4 
Signaling Pathways
In the canonical signaling pathways activated by 
ErbB4 and other receptor tyrosine kinases, sig-
nal transduction is initiated by the intact recep-
tor. New work by Sardi et al. (2006) shows that, 
in addition to its canonical functions, a cleaved 
intracellular domain of the JM-a isoform of 
ErbB4 translocates to the nucleus and repress-
es gene transcription. Binding of neuregulin 1 
(NRG1) to the extracellular ligand-binding re-
gion of ErbB4 stimulates receptor dimerization, 
tyrosine kinase activation, autophosphorylation, 
and recruitment of signaling proteins such as 
the adaptor proteins Shc and Grb2. Receptor 
stimulation leads to the activation of the Ras/
MAPK, PI3K/Akt, and phospholipase Cγ (PLCγ) 
cascades and the phosphorylation of STAT pro-
teins. The PI3K/Akt signaling cascade plays a 
critical role in stimulation of an antiapoptotic re-
sponse. Upon tyrosine phosphorylation and ac-
tivation, PLCγ stimulates phosphatidylinositol-
(4,5)-bisphosphate hydrolysis and Ca2+ release 
from cytoplasmic stores, leading to activation of 
serine/threonine kinases. STAT proteins dimer-
ize upon tyrosine phosphorylation and move to 
the nucleus to regulate gene transcription. When 
stimulated by neuregulin 1, the activated JM-a 
isoform of ErbB4 is also cleaved by TACE in the 
extracellular juxtamembrane region, releasing 
the ligand-binding domain of the receptor. The 
truncated receptor at the cell membrane is then 
cleaved in its transmembrane domain by a pre-
senilin γ-secretase to liberate an activated form of the ErbB4 intracellular domain, designated s80 or E4ICD. E4ICD interacts with the adaptor 
protein TAB2 that is bound to nuclear receptor corepressor (N-CoR). The ternary E4ICD/TAB2/N-CoR complex then moves to the nucleus, where 
it represses genes such as GFAP and S100 that prevent neuronal progenitor cells from developing into astrocytes.flanked by regulatory sequences that become tyrosine 
autophosphorylated in response to ligand stimulation 
and are also phosphorylated by several serine/threonine 
protein kinases. Autophosphorylated tyrosines in the C-
terminal regulatory region of ErbB4 act as docking sites 
for the adaptor proteins Grb2 and Shc and signaling 
proteins such as phospholipase Cγ (PLCγ), phosphati-
dylinositol 3-kinase (PI3K), and signal transduction and 
activators of transcription (STATs). The recruitment of 
these proteins activates downstream signaling pathways 
(Figure 1) (reviewed in Schlessinger, 2000; Blume-Jensen 
and Hunter, 2001; Pawson et al., 2001; Levy and Darnell, 
2002) that mediate many cellular processes.
Nuclear Translocation of a Cleaved ErbB4 
 Intracellular Domain
A unique feature of ErbB4 that sets this receptor apart from 
other EGFR family members is the existence of two alter-
natively spliced isoforms with different sequences in the 
extracellular juxtamembrane region, designated JM-a and 
JM-b (Elenius et al., 1997). The JM-a and JM-b isoforms of 
ErbB4 exhibit different tissue expression patterns. The JM-
a isoform is expressed exclusively in the kidney, uterus, and 
eye, whereas the JM-b isoform is expressed exclusively in 
heart and cerebral cortex; both isoforms are expressed 
in the cerebellum and spinal cord (Elenius et al., 1997). 
Whereas the JM-b isoform of ErbB4 functions primarily as 
a canonical RTK and signals from the cell surface, the JM-a 
isoform additionally employs the dual-protease (TACE/pre-46 Cell 127, October 6, 2006 ©2006 Elsevier Inc.senilin) signaling mechanism as described above, making 
it unique among RTKs. Stimulation with neuregulin at the 
cell surface promotes extracellular cleavage of the JM-a 
isoform of ErbB4 by TACE (Rio et al., 2000), which cleaves 
ErbB4 between His651 and Ser652 and liberates a soluble 
form of the extracellular ligand-binding region (reviewed in 
Carpenter, 2003b). The remaining membrane-anchored 
portion of ErbB4 (m80) is further cleaved within its trans-
membrane domain by a presenilin γ-secretase (Figure 1) 
to produce a soluble dimeric, active form of the intracel-
lular domain (ICD) of ErbB4, designated E4ICD or s80 (Ni 
et al., 2001; Lee et al., 2002; Carpenter, 2003b; Linggi and 
Carpenter, 2006; Linggi et al., 2006). Analysis of the cellular 
localization of E4ICD using fluorescence microscopy has 
demonstrated that E4ICD is translocated into the nucleus.
Nuclear ErbB4 Represses Transcription of 
 Neuronal Differentiation Genes
Sardi et al. (2006) used an activated form of E4ICD as 
a yeast two-hybrid bait for screening a cDNA expres-
sion library derived from rat embryonic spinal cord and 
dorsal root ganglia. One of the proteins found to interact 
with E4ICD was TAB2, previously identified as an adap-
tor molecule that participates in signaling downstream 
of interleukin-1 (IL-1). TAB2 forms a complex with TAK1, 
a protein kinase that plays a key role in IL-1 stimulation of 
NF-κB and JNK activation (Takaesu et al., 2000). Impor-
tantly, Sardi et al. demonstrated that complex formation 
between TAB2 and E4ICD is specific and is dependent 
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although TAB2 does not appear to become phosphory-
lated in response to ErbB4 activation by neuregulin 1. 
TAB2 interacts with either the JM-a or JM-b isoform of 
(intact) ErbB4 in a neuregulin-dependent manner. How-
ever, translocation of TAB2 to the nucleus (as part of a 
TAB2/E4ICD complex) only occurs following presenilin-
dependent cleavage of the JM-a isoform of ErbB4.
Consistent with previous studies demonstrating that 
TAB2 can also form a complex with the nuclear receptor 
corepressor N-CoR (Baek et al., 2002), a ternary E4ICD/
TAB2/N-CoR complex could be detected in lysates from 
neuregulin 1-stimulated cells that express the JM-a iso-
form of ErbB4. TAB2 may act as a “bridge” or adaptor 
molecule, constitutively associating with N-CoR through 
its amino terminus and recruiting the TAB2/N-CoR com-
plex to neuregulin 1-activated ErbB4 through its carboxyl 
terminus. Following presenilin-dependent cleavage of 
ErbB4 (JM-a), the TAB2/N-CoR complex remains asso-
ciated with the liberated E4ICD, and the ternary E4ICD/
TAB2/N-CoR complex undergoes nuclear translocation. 
Nuclear translocation is likely promoted by the nuclear 
localization sequence found in E4ICD because siRNA 
knockdown of TAB2 does not affect E4ICD nuclear local-
ization. The nuclear translocation of the ternary E4ICD/
TAB2/N-CoR complex represses transcription of several 
glial genes that are required for the differentiation of neu-
ronal precursor cells into astrocytes, including GFAP and 
S100β, although the precise mechanism of this repres-
sion and the basis for promoter selectivity have yet to be 
determined. Neuregulin 1 stimulation of neuronal precur-
sor cells antagonizes the ability of ciliary neurotrophic fac-
tor (CNTF) to promote astrogenesis, in part by repressing 
genes such as GFAP and S100β through the presenilin-
dependent mechanism outlined above, thereby maintain-
ing the neurogenic state. The canonical mode of ErbB4 
signaling cannot elicit these effects.
Sardi et al. (2006) used RNAi knockdown of TAB2 and 
ErbB4 to demonstrate that these molecules are critical for 
the inhibitory effect of neuregulin 1 on astrogenesis and 
GFAP expression. Chromatin immunoprecipitation assays 
also demonstrated that E4ICD associates with the GFAP 
and S100β promoters in a neuregulin 1-dependent man-
ner. From studies using genetically modified mice lacking 
ErbB4 in most tissues, the authors conclude that the timing 
of astrogenesis during embryonic development is deter-
mined by transcriptional repression promoted by direct 
nuclear action of the cleaved JM-a ErbB4 isoform. Astro-
genesis occurs later in development than neurogenesis, 
and nuclear ErbB4 signaling appears to play a key role in 
creating this delay by inhibiting the onset of astrogenesis. 
Mice deficient in ErbB4 show precocious cortical astro-
genesis, which can be rescued by expression of the cleav-
able JM-a isoform of ErbB4, but not by the JM-b isoform.
Intracellular signaling pathways that are activated by 
Notch, ErbB4, and other extracellular cues initiate a molec-
ular program in the early stages of embryonic development 
that preferentially stimulates neurogenesis over astrogen-esis. At this stage of embryonic development, astrogenesis 
is repressed by the presenilin-dependent action of the JM-
a isoform of ErbB4. At a later stage of embryonic develop-
ment, expression of the JM-a ErbB4 isoform in neuronal 
precursor cells is reduced, and this enables the induction 
of astrocyte development by other stimulatory signals (Fox 
and Kornblum, 2005). It is noteworthy that presenilin plays 
a positive role in the control of Notch-1 action by activating 
an intracellular signaling pathway that stimulates astrocyte 
development. It is expected, therefore, that a deficiency in 
presenilin will have only a minor effect on astrocyte devel-
opment because the reduced stimulation of Notch signal-
ing will be offset by the loss of inhibitory signaling through 
the JM-a isoform of ErbB4. Indeed, a minimal change in 
expression of markers for astrocyte development was 
detected in mice lacking presenilin.
Sardi et al. (2006) propose that the nuclear action of 
the JM-a isoform of ErbB4 also plays a role in the pathol-
ogy of Alzheimer’s disease (AD). This notion is based 
partly on the finding that ErbB4 is highly enriched in neu-
ronal plaques of AD patients. Moreover, it is well estab-
lished that APP, the major mediator of AD, is cleaved by 
a similar presenilin-dependent mechanism that results 
in the release of the APP cytoplasmic domain to medi-
ate its intracellular effects. Interestingly, the presenilin-
cleaved APP product interacts with TAB2 and N-CoR, 
the two partners of E4ICD shown to be responsible for 
mediating the transcriptional repression of astrocyte 
development. It is proposed that the common targets 
for the presenilin-cleaved forms of APP and ErbB4 may 
influence the transcriptional regulation of genes that 
lead to neurodegeneration.
Do Intact Receptors Move to and Act in the Nucleus?
There are also reports that intact RTKs may be trans-
located to the nucleus in a ligand-dependent manner 
(reviewed in Carpenter, 2003a; Krolewski, 2005; Massie 
and Mills, 2006), although our understanding of the 
mechanism underlying this process is extremely limited 
(Krolewski, 2005; Massie and Mills, 2006). In contrast 
to the convincing studies describing the signaling role 
of E4ICD in direct nuclear signaling by ErbB4, there has 
been no convincing demonstration that intact RTKs in 
the nucleus play an important signaling role.
It has been clear for decades that activated ligand/
receptor complexes formed on the cell-surface cluster 
in coated pit invaginations that then pinch off to become 
coated vesicles, which carry the occupied activated 
receptors inside the cell via receptor-mediated endocy-
tosis. However, is it possible that this provides a route for 
delivery of intact receptors to the nucleus? After endo-
cytosis, most internalized ligand/RTK complexes are 
delivered to lysosomes for degradation or are recycled 
(following ligand dissociation) back to the cell surface for 
reutilization by a fresh pool of soluble ligand molecules. 
It now also seems clear that internalized RTKs can acti-
vate intracellular signaling pathways while residing in 
intracellular vesicles following endocytosis. However, it 
is generally thought that the main function of internaliza-
tion of ligand/RTK complexes is to terminate the signal 
that is initiated at the cell surface.
An alternative school of thought is that an important role 
of endocytosis is to deliver ligand/RTK complexes into the 
cell interior to enable their translocation into the nucleus, 
where intact growth factors, RTKs alone, or growth fac-
tor/RTK complexes participate directly in regulating tran-
scriptional stimulation or repression of genes important in 
the control of cell proliferation, cell differentiation, and cell 
survival (reviewed in Krolewski, 2005; Massie and Mills, 
2006). Indeed, a large body of literature has accumulated 
over the past 25 years on nuclear signaling by a variety of 
growth factors (e.g., NGF, EGF, and FGF), hormones (e.g., 
insulin), and RTKs (e.g., insulin receptor, EGF receptor, 
FGF receptor, and NGF receptor) as well as intact ligands 
bound to their cognate receptors. This large body of work 
has been received with some skepticism for two main rea-
sons. First, in the context of our extensive knowledge of 
signaling by most of these receptors, it is currently not nec-
essary to invoke direct nuclear action of the receptors (or 
ligands) to explain their biological activities, although this 
naturally does not prove a lack of nuclear function. Second, 
the mechanisms proposed for the various steps involved in 
the movement of growth factors and RTKs from endocytic 
vesicles to the cytoplasm and nucleus have not been con-
vincing. For example, it was proposed that intact growth 
factors and RTKs that reside in the limiting membranes of 
endocytic vesicles might be extracted from these mem-
branes into the cytoplasm through retrotranslocation. In 
this model, retrotranslocation is mediated by the Sec61 
translocon (Carpenter, 2003a; Krolewski, 2005; Massie 
and Mills, 2006) in a process analogous to the endoplas-
mic reticulum (ER) associated degradation (ERAD) system 
that normally transports misfolded proteins from the ER to 
the cytoplasm for degradation by the ubiquitin proteasome 
system. How these receptors reach the ER (where Sec61 
is located), or whether Sec61 is ever found in endocytic 
vesicles, is far from established. It has been pointed out 
(Carpenter, 2003a; Massie and Mills, 2006) that certain 
toxins and viral proteins are thought to gain access to the 
ER, cytoplasm, and/or nucleus through such mechanisms. 
However, it is not clear how large multidomain proteins 
such as EGFR and other RTKs can be moved across 
cell membranes via a channel that normally functions to 
transport unfolded or misfolded proteins across cell mem-
branes. It is also not clear how RTKs that are transported 
by Sec61 into the cytoplasm would escape degradation by 
the Sec61-associated ubiquitination and proteasome sys-
tem. Given these conceptual difficulties and the fact that 
the molecular targets of nuclear growth factors and recep-
tors have not been adequately described, it may be that 
these reports reflect artifactual contaminants rather than 
genuine biologically significant components of the tran-
scriptional apparatus.
The experiments presented in the report of Sardi et al. 
(2006) represent one of the first robins of spring in this 
field. In contrast with the intact receptor studies, Sardi et 48 Cell 127, October 6, 2006 ©2006 Elsevier Inc.al. demonstrate clearly that ErbB4 participates in a bio-
logically significant signaling mechanism mediated by 
direct nuclear action of an activated ErbB4 fragment that 
is transported from the cell membrane to the nucleus 
in a manner that is regulated by a known ErbB4 ligand. 
In addition to its biological significance and functional 
credibility, there is also now a sophisticated understand-
ing of the molecular basis for this signaling process, 
although details remain to be elucidated. The collective 
work on ErbB4 nuclear signaling summarized here sets 
a standard with which to challenge all other studies of 
direct nuclear signaling by RTKs.
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